Related Experiment Video
Updated: Jul 25, 2026

Human Primary Trophoblast Cell Culture Model to Study the Protective Effects of Melatonin Against Hypoxia/reoxygenation-induced Disruption
Published on: July 30, 2016
Dysfunction of the cyclo-oxygenase pathway in the foetoplacental circulation in Type 1 diabetes mellitus
T M Bisseling1, A C Wouterse, E A P Steegers
1Department of Pharmacology-Toxicology, University Medical Cenger, Nijmegen, the Netherlands.
Insights
Diabetic pregnancies show impaired cyclo-oxygenase pathway function in the foetoplacental circulation. This dysfunction reduces the normal vasodilator effect of cyclo-oxygenase products, impacting fetal well-being.
Area of Science:
- Reproductive Medicine
- Vascular Biology
- Endocrinology
Background:
- Diabetes mellitus significantly increases perinatal morbidity.
- Functional changes in the fetoplacental vascular bed may contribute to this increased risk.
- Defects in the cyclo-oxygenase pathway are frequently observed in diabetes models.
Purpose of the Study:
- To investigate the hypothesis that the human fetoplacental circulation in diabetic patients exhibits cyclo-oxygenase pathway dysfunction.
- To quantify the contribution of cyclo-oxygenase products to fetoplacental vascular tone in diabetic versus healthy pregnancies.
Main Methods:
- Ex-vivo perfusion of isolated placental cotyledons from women with Type 1 diabetes (n=9) and healthy controls (n=14).
- Measurement of fetoplacental arterial pressure responses to the cyclo-oxygenase inhibitor indomethacin to assess pathway activity.
Main Results:
- Baseline fetoplacental arterial pressure was similar between control and diabetic groups.
- The increase in arterial pressure induced by indomethacin was significantly reduced in diabetic placentas compared to controls (2.9 mmHg vs. 11.2 mmHg, P=0.01).
Conclusions:
- Cyclo-oxygenase products normally exert a vasodilatory effect in the fetoplacental vascular bed.
- This vasodilatory effect appears significantly impaired in pregnancies complicated by diabetes.
Aim:
In diabetes, perinatal morbidity is significantly increased. This may partly be related to functional changes in the foetoplacental vascular bed. In diabetes models, a defect in the cyclo-oxygenase pathway is a common observation. Therefore, we hypothesized that the human foetoplacental circulation of diabetic patients is characterized by dysfunction of the cyclo-oxygenase pathway, as well.
Methods:
We performed ex-vivo perfusions of isolated placental cotyledons from healthy women (n = 14) and from patients with Type 1 diabetes (n = 9). The contribution of cyclo-oxygenase products to foetoplacental vascular tone was quantified by measuring the response to the cyclo-oxygenase inhibitor indomethacin.
Results:
Baseline foetoplacental arterial pressure was comparable between controls and diabetic women (mean +/- sem, 21.7 +/- 1.2 vs. 24.4 +/- 2.0 mmHg). Maximum foetoplacental arterial pressure at highest dose of indomethacin was 32.8 +/- 3.0 mmHg in controls vs. 27.3 +/- 2.3 mmHg in diabetic women. The indomethacin-induced increase in pressure was reduced in diabetes (2.9 +/- 0.7 vs. 11.2 +/- 2.4 mmHg in controls, P = 0.01).
Conclusions:
Under baseline conditions, the net effect of all cyclo-oxygenase products in the foetoplacental vascular bed is vasodilation. In diabetes, this vasodilator effect seems significantly impaired.
Related Concept Videos
Diabetes Mellitus: Overview and Type I Subtype
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Diabetes Mellitus: Type 2 and Gestational
Pathophysiology of Diabetes
Type 1 diabetes is characterized by autoimmune-mediated destruction of pancreatic β cells, with environmental factors potentially triggering this process in genetically susceptible individuals. Despite many not having a family history, certain genes increase susceptibility, suggesting a...
Diabetes Mellitus: Introduction
Type I Diabetes II: Pathophysiology
Type II Diabetes II: Pathophysiology

